Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma

Oncogene

Volumn 33, Issue 18, 2014, Pages 2354-2362

  Taulli, R ^a,b   Foglizzo, V ^a,b   Morena, D ^a,b   Coda, D M ^a,b   Ala, U ^c   Bersani, F ^a,b,d   Maestro, N ^a,b   Ponzetto, C ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CERMS   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

BAF53a; Chromatin remodeling; Differentiation therapy; MiR 206; Rhabdomyosarcoma

Indexed keywords

BAF53A PROTEIN; BARRIER TO AUTOINTEGRATION FACTOR; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DOWN REGULATION; FIBROBLAST; GENE EXPRESSION REGULATION; GENE SILENCING; HEK293 CELL LINE; HUMAN; HUMAN CELL; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SUBUNIT; RHABDOMYOSARCOMA; STABLE EXPRESSION; TUMOR DIFFERENTIATION; TUMOR GROWTH;

ACTINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; DOWN-REGULATION; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MUSCLE DEVELOPMENT; MUSCLE NEOPLASMS; MYOD PROTEIN; RHABDOMYOSARCOMA; SATELLITE CELLS, SKELETAL MUSCLE; TRANSCRIPTION FACTORS;

EID: 84899988165     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.188     Document Type: Article

References (49)

1. Ho L, Crabtree GR. Chromatin remodelling during development. Nature 2010; 463: 474-484.
2. Wu JI, Lessard J, Olave IA, Qiu Z, Ghosh A, Graef IA et al. Regulation of dendritic development by neuron-specific chromatin remodeling complexes. Neuron 2007; 56: 94-108.
3. Forcales SV, Albini S, Giordani L, Malecova B, Cignolo L, Chernov A et al. Signaldependent incorporation of MyoD-BAF60c into Brg1-based SWI/SNF chromatinremodelling complex. EMBO J 2011; 31: 301-316.
4. Krasteva V, Buscarlet M, Diaz-Tellez A, Bernard MA, Crabtree GR, Lessard JA. The BAF53a subunit of SWI/SNF-like BAF complexes is essential for hemopoietic stem cell function. Blood 2012; 120: 4720-4732.
5. Bao X, Tang J, Lopez-Pajares V, Tao S, Qu K, Crabtree GR et al. ACTL6a enforces the epidermal progenitors state by suppressing SWI/SNF-dependent induction of KLF4. Cell Stem Cell 2013; 12: 193-203.
6. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene 2009; 28: 1653-1668.
7. Roberts CW, Leroux MM, Fleming MD, Orkin SH. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2002; 2: 415-425.
8. DeCristofaro MF, Betz BL, Wang W, Weissman BE, Merlino G, Helman LJ. Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors. Oncogene 1999; 18: 7559-7565.
9. Merlino G, Helman LJ. Rhabdomyosarcoma-working out the pathways. Oncogene 1999; 18: 5340-5348.
10. Tapscott SJ, Thayer MJ, Weintraub H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 1993; 259: 1450-1453.
11. Xia SJ, Barr FG. Chromosome translocations in sarcomas and the emergence of oncogenic transcription factors. Eur J Cancer 2005; 41: 2513-2527.
12. McDowell HP. Update on childhood rhabdomyosarcoma. Arch Dis Child 2003; 88: 354-357.
13. Raney RB, Maurer HM, Anderson JR, Andrassy RJ, Donaldson SS, Qualman SJ et al. The Intergroup Rabdomyosarcoma Study Group. (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 2001; 5: 9-15.
14. Meyer WH, Spunt SL. Soft tissue sarcomas of childhood. Cancer Treat Rev 2004; 30: 269-280.
15. Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 2009; 119: 2366-2378.
16. Missiaglia E, Sheperd CJ, Patel S, Thway K, Pierron G, Pritchard-Jones K et al. MicroRNA-206 expression levels correlate with clinical behavior of rhabdomyosarcomas. Brit J Cancer 2010; 102: 1769-1777.
17. Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006; 66: 4742-4749.
18. Yan D, Dong Xda E, Chen X, Wang L, Lu C, Wang J et al. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 2009; 284: 29596-29604.
19. Macquarrie KL, Yao JM, Cao Y, Tapscott SJ. miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells. Skelet Muscle 2012; 2: 7.
20. Walters ZS, Villarejo-Balcells B, Olmos D, Buist TWS, Missiaglia E, Allen R et al. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene 2013; 1: 10.
21. Ohfuchi E, Nishimori K, Harata M. Alternative splicing products of the gene for a human nuclear actin-related protein, hArpNbeta/Baf53, that encode a protein isoform, hArpNbetaS, in the cytoplasm. Biosci Biotechnol Biochem 2002; 66: 1740-1743.
22. Rosenberg MI, Georges SA, Asawachaicharn A, Analau E, Tapscott SJ. MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206. J Cell Biol 2006; 175: 77-85.
23. Kim HK, Lee YS, Sivaprasad U, Malhotra A, Dutta A. Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol 2006; 174: 677-687.
24. Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y et al. miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun 2013; 13: 364.
25. Zhang L, Liu X, Jin H, Guo X, Xia L, Chen Z et al. Mir-206 inhibits cancer proliferation in part by repressing cyclinD2. Cancer Lett 2013; 332: 94-101.
26. Boutet SC, Cheung TH, Quach NL, Liu L, Prescott SL, Edalati A et al. Alternative polyadenylation mediates microRNAs regulation of muscle stem cell function. Cell Stem Cell 2012; 10: 327-336.
27. Chen JF, Tao Y, Li J, Deng Z, Yan Z, Xiao X et al. MicroRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. J Cell Biol 2010; 190: 867-879.
28. de la Serna IL, Carlson KA, Imbalzano AN. Mammalian SWI/SNF complexes promote MyoD-mediated muscle differentiation. Nat Genet 2001; 27: 187-190.
29. de la Serna IL, Roy K, Carlson KA, Imbalzano AN. MyoD can induce cell cycle arrest but not muscle differentiation in the presence of dominant negative SWI/SNF chromatin remodeling enzymes. J Biol Chem 2001; 276: 41486-41491.
30. Ohkawa Y, Yoshimura S, Higashi C, Marfella CG, Dacwag CS, Tachibana T et al. Myogenin and the SWI/SNF ATPase Brg1 maintain myogenic gene expression at different stages of skeletal myogenesis. J Biol Chem 2007; 282: 6564-6570.
31. Mallappa C, Nasipak BT, Etheridge L, Androphy EJ, Jones SN, Segerstrom CG et al. Myogenic microRNA expression requires ATP-dependent chromatin remodelling enzyme function. Mol Cell Biol 2010; 30: 3176-3186.
32. Yoo AS, Staahl BT, Chen L, Crabtree GR. MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. Nature 2009; 460: 642-646.
33. Wu JI. Diverse functions of ATP-dependent chromatin remodeling complexes in development and cancer. Acta Biochim Biophys Sin 2012; 44: 54-69.
34. Olave I, Wang W, Xue Y, Kuo A, Crabtree GR. Identification of a polymorphic, neuron-specific chromatin remodeling complex. Genes Dev 2002; 16: 2509-2517.
35. Goljanek-Whysall K, Pais H, Rathjen T, Sweetman D, Dalmay T, Münsterberg AE. Regulation of multiple target genes by mir-1 and miR-206 is pivotal for C2C12 myoblasts differentiation. J Cell Sci 2012; 125: 3590-3600.
36. Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd CJ et al. Distinct role for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J 2010; 24: 3427-3437.
37. Coutinho P, Albini S, Barbora M, Felsani A, Caruso M, Puri PL. Society for muscle biology, 'frontiers in myogenesis: development, function and repair of the muscle cell'. 4-8 June 2012NY, USA Abstract # 149.
38. Reyes JC, Barra J, Muchardt C, Camus A, Babinet C, Yaniv M. Altered control of cellular proliferation in the absence of mammalian brahma (SNF2a). EMBO J 1998; 17: 6979-6991.
39. BoucheM, Senni MI, Grossi AM, Zappelli F, Polimeni M, Arnold HH et al. TPA-induced differentiation of human rhabdomyosarcoma cells: expression of the myogenic regulatory factors. Exp Cell Res 1993; 208: 209-217.
40. Puri PL, Wu Z, Zhang P, Wood LD, Bhakta KS, Han J et al. Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev 2000; 14: 574-584.
41. Ricaud S, Vernus B, Duclos M, Bernardi H, Ritvos O, Carnac G et al. Inhibition of autocrine secretion of myostatin enhances terminal differentiation in human rhabdomyosarcoma cells. Oncogene 2003; 22: 8221-8232.
42. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008; 14: 369-381.
43. Yang Z, MacQuarrie KL, Analau E, Tyler AE, Dilworth FJ, Cao Y et al. MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. Genes Dev 2009; 23: 694-707.
44. Roma J, Masia A, Reventós J, Sánchez de Toledo J, Gallego S. Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro. Clin Cancer Res 2011; 17: 505-513.
45. Belyea B, Kephart JG, Blum J, Kirsch DG, Linardic CM. Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Sarcoma 2012, 2012: 406239.
46. Raimondi L, Ciarapica R, De Salvo M, Verginelli F, Gueguen M, Martini C et al. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo. Cell Death Differ 2012; 19: 871-881.
47. Taulli R, Bersani F, Ponzetto C. Micro-orchestrating differentiation in cancer. Cell Cycle 2010; 9: 918-922.
48. Williamson D, Missiaglia E, de Reynie( )s A, Pierron G, Thuille B, Palenzuela G et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010; 28: 2151-2158.
49. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25: 217-222.